INGR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Ingredion Inc (INGR) is not a strong buy at this moment for a beginner investor with a long-term strategy. While the company has shown strong growth in net income and EPS in the latest quarter, its revenue decline and bearish technical indicators suggest caution. Additionally, insider selling and mixed analyst ratings further weaken the case for immediate investment. A hold position is recommended until clearer positive trends emerge.
The technical indicators suggest a bearish trend. The MACD is below zero and negatively contracting, the RSI is neutral at 49.327, and moving averages indicate a bearish alignment (SMA_200 > SMA_20 > SMA_5). The stock is trading below the pivot level of 117.382, with key support at 115.213 and resistance at 119.552.
Univar Solutions' exclusive distribution agreement with Ingredion Pharma Solutions could enhance market share and customer base. Hedge funds have increased their buying activity by 137.50% over the last quarter.
Insider selling has surged significantly, with the CEO selling shares worth $4.02 million. The Q4 revenue decline and gross margin drop indicate ongoing challenges. Analysts have mixed ratings, with some lowering price targets due to weaker profits in key segments and facility-related headwinds.
In Q4 2025, Ingredion's revenue dropped by 2.39% YoY to $1.757 billion, while net income increased by 73.68% YoY to $165 million. EPS grew by 79.72% YoY to 2.57, but gross margin declined by 1.88% YoY to 24.47%.
Analyst ratings are mixed. UBS raised the price target to $124 but maintained a Neutral rating. BMO Capital lowered the price target to $120, citing weaker profits in key segments. Barclays raised the price target to $128 but highlighted facility-related headwinds. Overall, analysts appear cautious about the stock's near-term prospects.
